Thus, as one considers the important early clinical trials with CAR T directed against antigens such as IL13Rα2, HER2, and EGFR (Table 1), the lessons learned from these trials may be applied in the development of CAR-T specific, for the most challenging brain cancers which occur in children, including Histone 3.3 mutant paediatric glioma (16, 17). This evidence concerns the gene EGFR and central nervous system cancer.